Which patient benefits from early angiotensin-converting enzyme inhibition after myocardial infarction? Results of one-year serial echocardiographic follow-up from the Captopril and Thrombolysis Study (CATS)

CATS Coordination Center, St. Antonious Hospital, Nieuwegein, The Netherlands.

OBJECTIVES: In this study we sought to investigate the effect of intervention with captopril within 6 h of the onset of myocardial infarction on left ventricular volume and clinical symptoms of heart failure in relation to infarct size during a 1-year follow-up period. BACKGROUND: Remodeling of the heart starts in the early phase of myocardial infarction and is associated with an adverse prognosis. Angiotensin-converting enzyme inhibition started in the subacute or late phase after myocardial infarction has been shown to improve prognosis. METHODS: In the Captopril and Thrombolysis Study, 298 patients with a first anterior myocardial infarction treated with intravenous streptokinase were randomized to receive either oral captopril (25 mg three times a day) or placebo. The left ventricular volume index was assessed by two-dimensional echocardiography within 24 h, on days 3, 10 and 90 and after 1 year. RESULTS: A small but significant increase in left ventricular volume indexes was observed after 12 months. Using a random coefficient model, no significant treatment effect on left ventricular volumes could be detected. In contrast, when survival models were used, the occurrence of left ventricular dilation was significatnly lower in captopril-treated patients (p = 0.018). In addition, the incidence of heart failure was lower in the captopril group (p < 0.03). This effect appeared early and was most obvious in patients with a medium-sized infarct (p = 0.04) and was not present in large infarcts. CONCLUSIONS: Very early treatment with captopril after myocardial infarction significantly reduces the occurrence of early dilation and the progression to heart failure. These data underscore the importance of early treatment. Furthermore, patients with intermediate infarct size benefit the most from this treatment strategy.

This article has been cited by other articles:

				R. A. Kloner and D. S. Cannom Uncertainty on the Use of Aldosterone Antagonists for Primary Therapy for Sudden Cardiac Death in the Setting of Implanted Devices Circulation, June 12, 2007; 115(23): 2983 - 2989. [Full Text] [PDF]

				J. Abdulla, S. Barlera, R. Latini, L. Kjoller-Hansen, P. Sogaard, E. Christensen, L. Kober, and C. Torp-Pedersen A systematic review: Effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction Eur J Heart Fail, February 1, 2007; 9(2): 129 - 135. [Abstract] [Full Text] [PDF]

				N. S. Dhalla, M. R. Dent, P. S. Tappia, R. Sethi, J. Barta, and R. K. Goyal Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 31 - 45. [Abstract] [PDF]

				P. J de Kam, A. A Voors, F. Fici, D. J van Veldhuisen, and W. H van Gilst Review: The revised role of ACE-inhibition after myocardial infarction in the thrombolytic/primary PCI era Journal of Renin-Angiotensin-Aldosterone System, December 1, 2004; 5(4): 161 - 168. [Abstract] [PDF]

				M. Nian, P. Lee, N. Khaper, and P. Liu Inflammatory Cytokines and Postmyocardial Infarction Remodeling Circ. Res., June 25, 2004; 94(12): 1543 - 1553. [Abstract] [Full Text] [PDF]

				S. Delepine, A. P. Furber, F. Beygui, F. Prunier, P. Balzer, J.-J. Le Jeune, and P. Geslin 3-D MRI assessment of regional left ventricular systolic wall stress in patients with reperfused MI Am J Physiol Heart Circ Physiol, April 1, 2003; 284(4): H1190 - H1197. [Abstract] [Full Text] [PDF]

				H.L. Hillege, W.H. van Gilst, D.J. van Veldhuisen, G. Navis, D.E. Grobbee, P.A. de Graeff, and D. de Zeeuw Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial Eur. Heart J., March 1, 2003; 24(5): 412 - 420. [Abstract] [Full Text] [PDF]

				R. B. Felder, J. Francis, Z.-H. Zhang, S.-G. Wei, R. M. Weiss, and A. K. Johnson Heart failure and the brain: new perspectives Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R259 - R276. [Abstract] [Full Text] [PDF]

				P. Korn, A. Kroner, J. Schirnhofer, S. Hallstrom, O. Bernecker, R. Mallinger, M. Franz, H. Gasser, E. Wolner, and B. K. Podesser Quinaprilat during cardioplegic arrest in the rabbit to prevent ischemia-reperfusion injury J. Thorac. Cardiovasc. Surg., August 1, 2002; 124(2): 352 - 360. [Abstract] [Full Text] [PDF]

				P.-J. de Kam, A. A. Voors, J. Brouwer, M. St John Sutton, and W. H. van Gilst Approaches to statistical analysis of repeated echocardiographic measurements after myocardial infarction and its relation to heart failure: Application of a random-effects model Eur J Heart Fail, June 1, 2002; 4(3): 277 - 282. [Abstract] [Full Text] [PDF]

				M. St. John Sutton and C.H. Scott A prediction rule for left ventricular dilatation post-MI? Eur. Heart J., April 1, 2002; 23(7): 509 - 511. [Full Text] [PDF]

				P.J de Kam, G.L Nicolosi, A.A Voors, M.P van Den Berg, J Brouwer, D.J van Veldhuisen, S Barlera, A.P Maggioni, P Giannuzzi, P.L Temporelli, et al. Prediction of 6 months left ventricular dilatation after myocardial infarction in relation to cardiac morbidity and mortality. Application of a new dilatation model to GISSI-3 data Eur. Heart J., April 1, 2002; 23(7): 536 - 542. [Abstract] [Full Text] [PDF]

				M. Hayashi, T. Tsutamoto, A. Wada, K. Maeda, N. Mabuchi, T. Tsutsui, H. Horie, M. Ohnishi, and M. Kinoshita Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1820 - 1826. [Abstract] [Full Text] [PDF]

				P. J. de Kam, A. A. Voors, M. P. van den Berg, D. J. van Veldhuisen, J. Brouwer, H. J. G. M. Crijns, C. Borghi, E. Ambrosioni, J. S. Hochman, T. H. LeJemtel, et al. Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: Results of a meta-analysis of 845 patients J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2047 - 2053. [Abstract] [Full Text] [PDF]

				J. K. French, D. J. Amos, B. F. Williams, D. B. Cross, J. M. Elliott, H. H. Hart, M. G. Williams, R. M. Norris, N. G. Ashton, R. M. L. Whitlock, et al. Effects of early captopril administration after thrombolysis on regional wall motion in relation to infarct artery blood flow J. Am. Coll. Cardiol., January 1, 1999; 33(1): 139 - 145. [Abstract] [Full Text] [PDF]

				K. Sakata, M. Shirotani, H. Yoshida, and C. Kurata Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension J. Am. Coll. Cardiol., August 1, 1998; 32(2): 438 - 443. [Abstract] [Full Text] [PDF]

				Indications for ACE Inhibitors in the Early Treatment of Acute Myocardial Infarction : Systematic Overview of Individual Data From 100 000 Patients in Randomized Trials Circulation, June 9, 1998; 97(22): 2202 - 2212. [Abstract] [Full Text] [PDF]

				M. Oosterga, A. A. Voors, P.-J. de Kam, H. Schunkert, Y. M. Pinto, J. H. Kingma, and W. H. van Gilst Plasma Angiotensin-Converting Enzyme Activity and Left Ventricular Dilation After Myocardial Infarction Circulation, June 17, 1997; 95(12): 2607 - 2609. [Abstract] [Full Text]

				M. A. Pfeffer, S. C. Greaves, J. M. O. Arnold, R. J. Glynn, F. S. LaMotte, R. T. Lee, F. J. Menapace Jr, E. Rapaport, P. M. Ridker, J.-L. Rouleau, et al. Early Versus Delayed Angiotensin-Converting Enzyme Inhibition Therapy in Acute Myocardial Infarction : The Healing and Early Afterload Reducing Therapy Trial Circulation, June 17, 1997; 95(12): 2643 - 2651. [Abstract] [Full Text]